Accelerate your research career at the Mongan Institute! The 8-month Health Care Data & Delivery Science Certificate Program will help you get the skills and knowledge you need to improve health care quality, access, value, and equity. Apply today! mghmonganeducation.org/application

Remember Evusheld? Appears that sipavibart (generic name for AZD3152, brand name TBD) should come out soon (w/i a month)! Chatter on the street is a possible EUA Friday. Cost hopefully won’t be an issue. Any other barriers to consider? Leonard Calabrese Jeffrey Sparks MD MMSc Zach Wallace

"Deliberate efforts to address the cardiovascular risk in patients with #gout are likely to be required to reduce mortality.” Could SGLT2 inhibitors help to treat gout? A review from Mongan Institute researchers considers the evidence: hcplive.com/view/sglt2-inh…

Register now for the MGH Comprehensive Large Vessel #Vasculitis course 9/6/24 w optional #ultrasound workshop ✅️ cpd.partners.org/content/2024-c… #rheumatology #medtwitter #meded Zach Wallace #sebastianunizonymd Mark A. Matza, MD, MBA, RhMSUS Minna Kohler, MD, RhMSUS

Thirdly, a brilliant overview of IgG4-related disease by Zach Wallace, Guy Katz, MD, Yasmin Hernandez-Barco, MD & Matthew Baker M.D., M.S. So much practical information here, including pathogenesis, pitfalls of diagnosis, and approach to remission✨👇 doi.org/10.1093/rap/rk…

A great team effort with Guy Katz, MD Yasmin Hernandez-Barco, MD and Matthew Baker M.D., M.S. to provide a perspective that we hope will help clinicians managing #igg4rd IgG4RD

A wonderful piece written by a wonderful person ⁦TheDaoIndex⁩, thank you! This story hits home as it mirrors my own experiences. Karoshi - {Japanese  過労死: Death by Being Overworked} | RheumNow rheumnow.com/blog/karoshi-j…

Established to honor a founding member of The COVID-19 Global Rheumatology Alliance, colleague, friend, & leader in #rheum, the Phil Robinson Global Scholars Program provides scholarships to register for, travel to, & attend #ACR24 in Washington, D.C. Must be an early career #rheum/trainee, #rheum

Many people with rheumatic disease have higher risk for long COVID. However, that risk has significantly decreased since the beginning of the pandemic, according to a new #NIAMSfunded study. Read the #OpenAccess paper via The Journal of Rheumatology: jrheum.org/content/early/…

#MassGeneral physician Zach Wallace was quoted in Medscape's article on research which found that patients with granulomatosis with polyangiitis who scored high on a sinonasal symptom test are nearly three times as likely to relapse. medscape.com/viewarticle/si…

In recognition of Mental Health Awareness Month, we're exploring different rare disease perspectives, including that of Damon Brooks. Damon, a Person of Color living with IgG4-RD, shares his experience navigating IgG4-RD, & the advice he’d give to others. shorturl.at/lvJPY

Pleased to have the chance to write this with Sebastian E. Sattui MD, MS.

It is #NationalGoutAwarenessDay. #Gout is form of #arthritis that causes severe pain, swelling, redness, & tenderness in joints. Here are some of our teams studies and findings on this #inflammatory disease.

Inebilizumab hit its primary and key secondary endpoints for #IgG4RD. Huge moment for the IgG4-RD community! Looking forward to full results. wwwext.amgen.com/newsroom/press…..

📣 #Uplizna met all endpoints for treatment of IgG4-RD in a placebo-controlled trial, Amgen 🧪🔬🧬 announced “For the first time, we know that there is an effective therapy to treat patients living with IgG4-RD,” Dr. Zachary Wallace told us Find out more ⬇️ healio.com/news/rheumatol…

With Amgen 🧪🔬🧬 announcing the positive results for the Phase 3 Registrational Trial evaluating Uplizna® (inebilizumab) for treatment of IgG4-related disease, today is a monumental day for the IgG4-RD community. Learn more: shorturl.at/oYtM1 #IgG4RD #ClinicalTrials

Call for applications for the Phil Robinson Global Scholars Program at #ACR24. Must be an early career #rheum/trainee, #rheum professional/trainee, or patient advocate outside of the U.S. & Canada to apply. Deadline June 28. Learn more → acr.tw/3q4j2eJ

Mats Junek presenting risk factors for relapse of ANCA associated vasculitis from #pexivas at #eular24 PR3 & non-DAH lung manifestations ⬆️ risk Dialysis ⬇️ risk PLEX and GC regimen no effect

Major thanks to everyone who contributed to this team effort and Annals of the Rheumatic Diseases for sharing our work. More to come on the role of complement in IgG4-related disease! Zach Wallace Alfred Kim MGH Rheumatology MGH Rheumatology & Allergy Clin Epi Research 7/7

IgG4-related disease Nearly any organ can be affected ▶️Salivary glands ▶️Lacrimal glands ▶️Orbit ▶️Pancreatobiliary system ▶️Lung ▶️Kidney ▶️Retroperitoneum 👉🏽academic.oup.com/rheumap/articl… via Rheumatology & Rheumatology Advances in Practice